FDA Nixes Bid For 'Special Flexibility' For Orphan Drugs
The U.S. Food and Drug Administration on Thursday declined a request from the National Organization for Rare Disorders to officially provide "special flexibility" when reviewing applications for orphan drugs, saying that...To view the full article, register now.
Already a subscriber? Click here to view full article